Prashant Kumar, CSO-DATAR CANCER GENETICS

Luminaries who have revolutionized the field of genomics and transforming clinical diagnosis and precision medicine @ril_foundation Hospital, Mumbai. A phenomenal Scientific Program with a focus on personalised medicine in tailoring treatment to patient.

ADCs are evolving from targeted cytotoxics into modular therapeutic platforms, enabling more precise biomarker-guided sequencing and next-generation engineered designs.

CAR-T Cell Therapy • Genetically engineered peripheral T cells expressing chimeric antigen receptors • Antigen recognition independent of MHC TIL Cell Therapy • Expansion of tumor-infiltrating lymphocytes derived directly from tumor tissue • Polyclonal recognition of tumor

@medanta patna organises a congregation on Cell and Gene Therapy (CGT). Speakers dwelt on requirement of bench to bedside capabilities of emerging Bihar. Keynote speaker Dr Chintoo Sudheish Kumar spoke on the role of innovations. @TOIIndiaNews @pranabsamanta @pankaj_p_sahni

A small chance meeting yet interactive one with none other than @DrvijayPatil11, the man behind inclusion of Triple oral metronomic chemotherapy and low-dose Nivolumab. Problems of LMIC countries will be solved by LMIC people. @JCO_ASCO @ASCO @ESMO @medanta @MoHFW_INDIA

@Doc_Amarendra Thanks!!!

CRISPR-Cas9 and Cancer: From Understanding DNA… to Rewriting the Future of Oncology

A conversation @SewantiLimaye, the session will explore the expanding applications, real-world utility, and future potential of Liquid Biopsy 🔬 A unique opportunity to learn, engage, and advance your understanding! 🎯 Register now and be part of the dialogue! 💬 Share Questions!

See this Instagram post by @apollo.athenaa instagram.com/reel/DWN8-blAl…

Microbiome profiling holds promise for improving treatment response prediction, immune modulation strategies, and personalized oncology approaches in lung cancer.

@apollo.athenaa instagram.com/reel/DWN8-blAl…

Where Liquid Biopsy Offers Advantages: 1. Clinical Monitoring 2. Assessing Dynamics 3. Minimal Residual Disease (MRD) 4. Longitudinal Profiling Where Tissue Biopsy Indispensable: 1. Definitive Typing 2. Structural Insights 3. Immunohistochemistry (IHC) 4. Prognostic Accuracy

The landscape of cervical cancer management has undergone a revolutionary transformation. From de-escalating surgery to the "Immunotherapy Era" in locally advanced disease, we are seeing survival curves we once thought impossible.